TY - JOUR
T1 - Identifying and predicting amyotrophic lateral sclerosis clinical subgroups
T2 - a population-based machine-learning study
AU - PARALS consortium
AU - ERRALS consortium
AU - Faghri, Faraz
AU - Brunn, Fabian
AU - Dadu, Anant
AU - Chiò, Adriano
AU - Calvo, Andrea
AU - Moglia, Cristina
AU - Canosa, Antonio
AU - Manera, Umberto
AU - Vasta, Rosario
AU - Palumbo, Francesca
AU - Bombaci, Alessandro
AU - Grassano, Maurizio
AU - Brunetti, Maura
AU - Casale, Federico
AU - Fuda, Giuseppe
AU - Salamone, Paolina
AU - Iazzolino, Barbara
AU - Peotta, Laura
AU - Cugnasco, Paolo
AU - De Marco, Giovanni
AU - Torrieri, Maria Claudia
AU - Gallone, Salvatore
AU - Barberis, Marco
AU - Sbaiz, Luca
AU - Gentile, Salvatore
AU - Mauro, Alessandro
AU - Mazzini, Letizia
AU - De Marchi, Fabiola
AU - Corrado, Lucia
AU - D'Alfonso, Sandra
AU - Bertolotto, Antonio
AU - Imperiale, Daniele
AU - De Mattei, Marco
AU - Amarù, Salvatore
AU - Comi, Cristoforo
AU - Labate, Carmelo
AU - Poglio, Fabio
AU - Ruiz, Luigi
AU - Testa, Lucia
AU - Rota, Eugenia
AU - Ghiglione, Paolo
AU - Launaro, Nicola
AU - Di Sapio, Alessia
AU - Mandrioli, Jessica
AU - Fini, Nicola
AU - Martinelli, Ilaria
AU - Zucchi, Elisabetta
AU - Gianferrari, Giulia
AU - Simonini, Cecilia
AU - Campbell, Roy H.
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2022/5
Y1 - 2022/5
N2 - Background: Amyotrophic lateral sclerosis (ALS) is known to represent a collection of overlapping syndromes. Various classification systems based on empirical observations have been proposed, but it is unclear to what extent they reflect ALS population substructures. We aimed to use machine-learning techniques to identify the number and nature of ALS subtypes to obtain a better understanding of this heterogeneity, enhance our understanding of the disease, and improve clinical care. Methods: In this retrospective study, we applied unsupervised Uniform Manifold Approximation and Projection [UMAP]) modelling, semi-supervised (neural network UMAP) modelling, and supervised (ensemble learning based on LightGBM) modelling to a population-based discovery cohort of patients who were diagnosed with ALS while living in the Piedmont and Valle d'Aosta regions of Italy, for whom detailed clinical data, such as age at symptom onset, were available. We excluded patients with missing Revised ALS Functional Rating Scale (ALSFRS-R) feature values from the unsupervised and semi-supervised steps. We replicated our findings in an independent population-based cohort of patients who were diagnosed with ALS while living in the Emilia Romagna region of Italy. Findings: Between Jan 1, 1995, and Dec 31, 2015, 2858 patients were entered in the discovery cohort. After excluding 497 (17%) patients with missing ALSFRS-R feature values, data for 42 clinical features across 2361 (83%) patients were available for the unsupervised and semi-supervised analysis. We found that semi-supervised machine learning produced the optimum clustering of the patients with ALS. These clusters roughly corresponded to the six clinical subtypes defined by the Chiò classification system (ie, bulbar, respiratory, flail arm, classical, pyramidal, and flail leg ALS). Between Jan 1, 2009, and March 1, 2018, 1097 patients were entered in the replication cohort. After excluding 108 (10%) patients with missing ALSFRS-R feature values, data for 42 clinical features across 989 patients were available for the unsupervised and semi-supervised analysis. All 1097 patients were included in the supervised analysis. The same clusters were identified in the replication cohort. By contrast, other ALS classification schemes, such as the El Escorial categories, Milano-Torino clinical staging, and King's clinical stages, did not adequately label the clusters. Supervised learning identified 11 clinical parameters that predicted ALS clinical subtypes with high accuracy (area under the curve 0·982 [95% CI 0·980–0·983]). Interpretation: Our data-driven study provides insight into the ALS population substructure and confirms that the Chiò classification system successfully identifies ALS subtypes. Additional validation is required to determine the accuracy and clinical use of these algorithms in assigning clinical subtypes. Nevertheless, our algorithms offer a broad insight into the clinical heterogeneity of ALS and help to determine the actual subtypes of disease that exist within this fatal neurodegenerative syndrome. The systematic identification of ALS subtypes will improve clinical care and clinical trial design. Funding: US National Institute on Aging, US National Institutes of Health, Italian Ministry of Health, European Commission, University of Torino Rita Levi Montalcini Department of Neurosciences, Emilia Romagna Regional Health Authority, and Italian Ministry of Education, University, and Research. Translations: For the Italian and German translations of the abstract see Supplementary Materials section.
AB - Background: Amyotrophic lateral sclerosis (ALS) is known to represent a collection of overlapping syndromes. Various classification systems based on empirical observations have been proposed, but it is unclear to what extent they reflect ALS population substructures. We aimed to use machine-learning techniques to identify the number and nature of ALS subtypes to obtain a better understanding of this heterogeneity, enhance our understanding of the disease, and improve clinical care. Methods: In this retrospective study, we applied unsupervised Uniform Manifold Approximation and Projection [UMAP]) modelling, semi-supervised (neural network UMAP) modelling, and supervised (ensemble learning based on LightGBM) modelling to a population-based discovery cohort of patients who were diagnosed with ALS while living in the Piedmont and Valle d'Aosta regions of Italy, for whom detailed clinical data, such as age at symptom onset, were available. We excluded patients with missing Revised ALS Functional Rating Scale (ALSFRS-R) feature values from the unsupervised and semi-supervised steps. We replicated our findings in an independent population-based cohort of patients who were diagnosed with ALS while living in the Emilia Romagna region of Italy. Findings: Between Jan 1, 1995, and Dec 31, 2015, 2858 patients were entered in the discovery cohort. After excluding 497 (17%) patients with missing ALSFRS-R feature values, data for 42 clinical features across 2361 (83%) patients were available for the unsupervised and semi-supervised analysis. We found that semi-supervised machine learning produced the optimum clustering of the patients with ALS. These clusters roughly corresponded to the six clinical subtypes defined by the Chiò classification system (ie, bulbar, respiratory, flail arm, classical, pyramidal, and flail leg ALS). Between Jan 1, 2009, and March 1, 2018, 1097 patients were entered in the replication cohort. After excluding 108 (10%) patients with missing ALSFRS-R feature values, data for 42 clinical features across 989 patients were available for the unsupervised and semi-supervised analysis. All 1097 patients were included in the supervised analysis. The same clusters were identified in the replication cohort. By contrast, other ALS classification schemes, such as the El Escorial categories, Milano-Torino clinical staging, and King's clinical stages, did not adequately label the clusters. Supervised learning identified 11 clinical parameters that predicted ALS clinical subtypes with high accuracy (area under the curve 0·982 [95% CI 0·980–0·983]). Interpretation: Our data-driven study provides insight into the ALS population substructure and confirms that the Chiò classification system successfully identifies ALS subtypes. Additional validation is required to determine the accuracy and clinical use of these algorithms in assigning clinical subtypes. Nevertheless, our algorithms offer a broad insight into the clinical heterogeneity of ALS and help to determine the actual subtypes of disease that exist within this fatal neurodegenerative syndrome. The systematic identification of ALS subtypes will improve clinical care and clinical trial design. Funding: US National Institute on Aging, US National Institutes of Health, Italian Ministry of Health, European Commission, University of Torino Rita Levi Montalcini Department of Neurosciences, Emilia Romagna Regional Health Authority, and Italian Ministry of Education, University, and Research. Translations: For the Italian and German translations of the abstract see Supplementary Materials section.
UR - http://www.scopus.com/inward/record.url?scp=85128785021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128785021&partnerID=8YFLogxK
U2 - 10.1016/S2589-7500(21)00274-0
DO - 10.1016/S2589-7500(21)00274-0
M3 - Article
C2 - 35341712
AN - SCOPUS:85128785021
SN - 2589-7500
VL - 4
SP - e359-e369
JO - The Lancet Digital Health
JF - The Lancet Digital Health
IS - 5
ER -